Effects of high glucose on interleukin-6 production in human mesangial cells.

Chun Gyoo Ihm, Jae Kyung Park, Hee Jin Kim, Tae Won Lee, Dae-Ryong Cha

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Interleukin (IL)-6 is an autocrine growth factor for mesangial cells. It is not known whether high glucose influences IL-6 production in mesangial cells. Angiotensin II (AGII) is involved in the progression of renal diseases including diabetic nephropathy. Therefore, we evaluated the effects of high glucose in concert with AGII on IL-6 production in human mesangial cells and the modulation by blocking AGII. After 48 hr of culture, IL-6 mRNA expression was analyzed by reverse transcription and polymerase chain reaction (PCR). Quantitative determination of IL-6 concentrations in the culture supernatants of mesangial cells was performed using a sandwich enzyme immunoassay kit. Incubation of mesangial cells with high glucose (450 mg/dL) reduced the ratio of PCR products for IL-6 to beta-actin on densitometric results, while AGII (10(-7)M) increased it. The IL-6 secretion in the supernatant was also increased by AGII and decreased by high glucose. The IL-6 mRNA expression and IL-6 secretion in combination of high glucose and AGII were higher than those in high glucose and similar with those in control media. The addition of losartan (10(-6)M) or captopril (10(-6)M) to high glucose had no additional effects on IL-6 production. These results suggest that whereas AGII increases IL-6 production, high glucose decreases it. The IL-6 production of mesangial cells in diabetic milieu may be complicated and depend on the local effects of high glucose and/or AGII.

Original languageEnglish
Pages (from-to)208-212
Number of pages5
JournalJournal of Korean Medical Science
Volume17
Issue number2
Publication statusPublished - 2002 Apr 1
Externally publishedYes

Fingerprint

Mesangial Cells
Interleukin-6
Glucose
Angiotensin II
Polymerase Chain Reaction
Messenger RNA
Losartan
Captopril
Diabetic Nephropathies
Immunoenzyme Techniques
Reverse Transcription
Disease Progression
Actins
Intercellular Signaling Peptides and Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of high glucose on interleukin-6 production in human mesangial cells. / Ihm, Chun Gyoo; Park, Jae Kyung; Kim, Hee Jin; Lee, Tae Won; Cha, Dae-Ryong.

In: Journal of Korean Medical Science, Vol. 17, No. 2, 01.04.2002, p. 208-212.

Research output: Contribution to journalArticle

Ihm, Chun Gyoo ; Park, Jae Kyung ; Kim, Hee Jin ; Lee, Tae Won ; Cha, Dae-Ryong. / Effects of high glucose on interleukin-6 production in human mesangial cells. In: Journal of Korean Medical Science. 2002 ; Vol. 17, No. 2. pp. 208-212.
@article{f56d427c7a0c421ebb718243034ae650,
title = "Effects of high glucose on interleukin-6 production in human mesangial cells.",
abstract = "Interleukin (IL)-6 is an autocrine growth factor for mesangial cells. It is not known whether high glucose influences IL-6 production in mesangial cells. Angiotensin II (AGII) is involved in the progression of renal diseases including diabetic nephropathy. Therefore, we evaluated the effects of high glucose in concert with AGII on IL-6 production in human mesangial cells and the modulation by blocking AGII. After 48 hr of culture, IL-6 mRNA expression was analyzed by reverse transcription and polymerase chain reaction (PCR). Quantitative determination of IL-6 concentrations in the culture supernatants of mesangial cells was performed using a sandwich enzyme immunoassay kit. Incubation of mesangial cells with high glucose (450 mg/dL) reduced the ratio of PCR products for IL-6 to beta-actin on densitometric results, while AGII (10(-7)M) increased it. The IL-6 secretion in the supernatant was also increased by AGII and decreased by high glucose. The IL-6 mRNA expression and IL-6 secretion in combination of high glucose and AGII were higher than those in high glucose and similar with those in control media. The addition of losartan (10(-6)M) or captopril (10(-6)M) to high glucose had no additional effects on IL-6 production. These results suggest that whereas AGII increases IL-6 production, high glucose decreases it. The IL-6 production of mesangial cells in diabetic milieu may be complicated and depend on the local effects of high glucose and/or AGII.",
author = "Ihm, {Chun Gyoo} and Park, {Jae Kyung} and Kim, {Hee Jin} and Lee, {Tae Won} and Dae-Ryong Cha",
year = "2002",
month = "4",
day = "1",
language = "English",
volume = "17",
pages = "208--212",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "2",

}

TY - JOUR

T1 - Effects of high glucose on interleukin-6 production in human mesangial cells.

AU - Ihm, Chun Gyoo

AU - Park, Jae Kyung

AU - Kim, Hee Jin

AU - Lee, Tae Won

AU - Cha, Dae-Ryong

PY - 2002/4/1

Y1 - 2002/4/1

N2 - Interleukin (IL)-6 is an autocrine growth factor for mesangial cells. It is not known whether high glucose influences IL-6 production in mesangial cells. Angiotensin II (AGII) is involved in the progression of renal diseases including diabetic nephropathy. Therefore, we evaluated the effects of high glucose in concert with AGII on IL-6 production in human mesangial cells and the modulation by blocking AGII. After 48 hr of culture, IL-6 mRNA expression was analyzed by reverse transcription and polymerase chain reaction (PCR). Quantitative determination of IL-6 concentrations in the culture supernatants of mesangial cells was performed using a sandwich enzyme immunoassay kit. Incubation of mesangial cells with high glucose (450 mg/dL) reduced the ratio of PCR products for IL-6 to beta-actin on densitometric results, while AGII (10(-7)M) increased it. The IL-6 secretion in the supernatant was also increased by AGII and decreased by high glucose. The IL-6 mRNA expression and IL-6 secretion in combination of high glucose and AGII were higher than those in high glucose and similar with those in control media. The addition of losartan (10(-6)M) or captopril (10(-6)M) to high glucose had no additional effects on IL-6 production. These results suggest that whereas AGII increases IL-6 production, high glucose decreases it. The IL-6 production of mesangial cells in diabetic milieu may be complicated and depend on the local effects of high glucose and/or AGII.

AB - Interleukin (IL)-6 is an autocrine growth factor for mesangial cells. It is not known whether high glucose influences IL-6 production in mesangial cells. Angiotensin II (AGII) is involved in the progression of renal diseases including diabetic nephropathy. Therefore, we evaluated the effects of high glucose in concert with AGII on IL-6 production in human mesangial cells and the modulation by blocking AGII. After 48 hr of culture, IL-6 mRNA expression was analyzed by reverse transcription and polymerase chain reaction (PCR). Quantitative determination of IL-6 concentrations in the culture supernatants of mesangial cells was performed using a sandwich enzyme immunoassay kit. Incubation of mesangial cells with high glucose (450 mg/dL) reduced the ratio of PCR products for IL-6 to beta-actin on densitometric results, while AGII (10(-7)M) increased it. The IL-6 secretion in the supernatant was also increased by AGII and decreased by high glucose. The IL-6 mRNA expression and IL-6 secretion in combination of high glucose and AGII were higher than those in high glucose and similar with those in control media. The addition of losartan (10(-6)M) or captopril (10(-6)M) to high glucose had no additional effects on IL-6 production. These results suggest that whereas AGII increases IL-6 production, high glucose decreases it. The IL-6 production of mesangial cells in diabetic milieu may be complicated and depend on the local effects of high glucose and/or AGII.

UR - http://www.scopus.com/inward/record.url?scp=0036551559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036551559&partnerID=8YFLogxK

M3 - Article

C2 - 11961304

AN - SCOPUS:0036551559

VL - 17

SP - 208

EP - 212

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 2

ER -